Generating & Validating an Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression

Time: 9:30 am
day: Conference Day Two

Details:

• Developing a prognostic biosignature of clinical progression in preclinical and mild cognitive impairment (MCI) due to AD individuals
• Harmonizing fluid biomarker measures across assay platforms and cohorts
• Investigating combinations of blood-blood markers (BBMs) and health status indicators that best forecast a change in cognitive/ functional scores